Immunome, Inc. (NASDAQ:IMNM – Get Free Report) has been given a consensus rating of “Buy” by the six brokerages that are covering the firm, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating. The average 12 month price objective among brokers that have covered the stock in the last year is $23.33.
Several equities research analysts recently weighed in on the company. Wall Street Zen upgraded Immunome from a “sell” rating to a “hold” rating in a report on Thursday, May 22nd. Stephens restated an “overweight” rating and set a $30.00 target price on shares of Immunome in a report on Thursday, March 20th. Wedbush restated an “outperform” rating and set a $21.00 target price (down from $33.00) on shares of Immunome in a report on Tuesday, May 13th. Lifesci Capital assumed coverage on Immunome in a report on Tuesday, March 11th. They set an “outperform” rating and a $20.00 target price for the company. Finally, Lake Street Capital began coverage on Immunome in a report on Wednesday, April 2nd. They set a “buy” rating and a $23.00 target price for the company.
View Our Latest Report on Immunome
Insiders Place Their Bets
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in the company. Voya Investment Management LLC raised its position in shares of Immunome by 21.2% in the 1st quarter. Voya Investment Management LLC now owns 18,905 shares of the company’s stock worth $127,000 after acquiring an additional 3,305 shares in the last quarter. Rhumbline Advisers raised its position in shares of Immunome by 30.4% in the 1st quarter. Rhumbline Advisers now owns 88,888 shares of the company’s stock worth $598,000 after acquiring an additional 20,721 shares in the last quarter. Woodline Partners LP raised its position in shares of Immunome by 69.0% in the 1st quarter. Woodline Partners LP now owns 1,657,729 shares of the company’s stock worth $11,157,000 after acquiring an additional 676,804 shares in the last quarter. Zimmer Partners LP bought a new position in shares of Immunome in the 1st quarter worth approximately $673,000. Finally, Exome Asset Management LLC bought a new position in shares of Immunome in the 1st quarter worth approximately $1,776,000. Institutional investors own 44.58% of the company’s stock.
Immunome Price Performance
Shares of IMNM stock opened at $8.74 on Thursday. The stock has a market capitalization of $760.48 million, a PE ratio of -2.75 and a beta of 1.94. Immunome has a 1-year low of $5.15 and a 1-year high of $16.81. The business has a 50-day moving average of $8.52 and a 200 day moving average of $9.23.
Immunome (NASDAQ:IMNM – Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.66) by $0.14. The company had revenue of $2.93 million during the quarter, compared to analysts’ expectations of $0.46 million. Immunome had a negative return on equity of 71.65% and a negative net margin of 1,875.21%. Analysts anticipate that Immunome will post -2.21 EPS for the current year.
About Immunome
Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.
See Also
- Five stocks we like better than Immunome
- What Are Treasury Bonds?
- Microsoft Stock Holds Steady as AI Drives Workforce Shift
- What is Insider Trading? What You Can Learn from Insider Trading
- D-Wave Goes International With South Korea Partnership
- What is a SEC Filing?
- Payment Giants Slide on Stablecoin Buzz—Is Now the Time to Buy?
Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.